2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. PDGFR

PDGFR

Platelet-derived growth factor receptor

PDGFR

Related Products

PDF 1.46 MB

PDGFR (Platelet-derived growth factor receptors) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGFR: PDGFR alpha and PDGFR beta.

PDGFR Isoform Specific Products:

PDGFR Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100315
    XL 999
    		Inhibitor 99.01%
    XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC50 values for VEGFR2/KDR/Flk-1, Flt-1, FGFR1 and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer.
    XL 999
  • HY-10981S
    Lenvatinib-d4
    		Inhibitor 99.59%
    Lenvatinib-d4 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].
    Lenvatinib-d<sub>4</sub>
  • HY-100368
    MELK-8a
    		98.32%
    MELK-8a (NVS-MELK8a) is a highly potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor with IC50 of 2 nM. MELK-8a also inhibits Flt3 (ITD), Haspin, PDGFRα with IC50s of 0.18, 0.19, and 0.42 μM, respectively. MELK plays an essential role in regulating cell mitosis in a subset of cancer cells.
    MELK-8a
  • HY-10527C
    Telatinib mesylate
    		Inhibitor 99.74%
    Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active VEGFR2/KDR/Flk-1, VEGFR3/Flt-4, PDGFα, and c-Kit inhibitor with IC50s of 6 nM, 4 nM, 15 nM and 1 nM, respectively.
    Telatinib mesylate
  • HY-101489A
    GZD856 formic
    		Inhibitor
    GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity. GZD856 (formic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    GZD856 formic
  • HY-15198
    KG5
    		Inhibitor 99.79%
    KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3, KIT and c-Raf. KG5 has anticancer, antiangiogenic activities.
    KG5
  • HY-12009S
    Pazopanib-13C,d3 hydrochloride
    Pazopanib-13C,d3 (hydrochloride) is the deuterium and 13C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].
    Pazopanib-<sup>13</sup>C,d<sub>3</sub> hydrochloride
  • HY-19624
    NVP-ACC789
    		Inhibitor 99.52%
    NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.
    NVP-ACC789
  • HY-10331S
    Regorafenib-d3
    		Inhibitor ≥98.0%
    Regorafenib-d3 is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].
    Regorafenib-d<sub>3</sub>
  • HY-116111
    AG 370
    		Inhibitor
    AG 370, an indole tyrphostin, is a potent PDGF-induced mitogenesis inhibotor (IC50 of 20 μM). AG 370 displays weak inhibition of the EGF receptor.
    AG 370
  • HY-120640
    BMS-605541
    		Inhibitor 99.57%
    BMS-605541 is a selective and orally active inhibitor of VEGFR-2 kinase with an IC50 value of 23 nM and Ki value of 49 nM. BMS-605541 inhibits the activity of VEGFR2/KDR/Flk-1, VEGFR-1 and PDGFR-β with IC50 values of 40 nM, 400 nM and 200 nM, respectively. BMS-605541 can be used for cancer research.
    BMS-605541
  • HY-15463S2
    Imatinib-d3 hydrochloride
    Imatinib-d3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
    Imatinib-d<sub>3</sub> hydrochloride
  • HY-10208S
    Pazopanib-d6
    		Inhibitor ≥98.0%
    Pazopanib-d6 is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
    Pazopanib-d<sub>6</sub>
  • HY-10255AS
    Sunitinib-d10
    		Inhibitor 99.89%
    Sunitinib-d10 is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2/KDR/Flk-1 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].
    Sunitinib-d<sub>10</sub>
  • HY-12047S
    Ponatinib-d8
    		Inhibitor 99.91%
    Ponatinib-d8 is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2/KDR/Flk-1, FGFR1, and Src, respectively.
    Ponatinib-d<sub>8</sub>
  • HY-10981R
    Lenvatinib (Standard)
    		Inhibitor
    Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
    Lenvatinib (Standard)
  • HY-RS10254
    PDGFRA Human Pre-designed siRNA Set A
    		Inhibitor

    PDGFRA Human Pre-designed siRNA Set A contains three designed siRNAs for PDGFRA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PDGFRA Human Pre-designed siRNA Set A
    PDGFRA Human Pre-designed siRNA Set A
  • HY-P99402
    Rinucumab
    		Inhibitor 98.89%
    Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration.
    Rinucumab
  • HY-10184
    TG 100572
    		Inhibitor
    TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    TG 100572
  • HY-108627
    DMPQ dihydrochloride
    		Inhibitor 99.10%
    DMPQ dihydrochloride is a potent and selective inhibitor of human platelet-derived growth factor receptor β (PDGFRβ) with an IC50 of 80 nM.
    DMPQ dihydrochloride
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
PDGFR Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.